No results found

Your search did not match any results.

We suggest you try the following to help find what you're looking for:

  • Check the spelling of your keyword search.
  • Use synonyms for the keyword you typed, for example, try “application” instead of “software.”
  • Try one of the popular searches shown below.
  • Start a new search.
Trending Questions
Press Release

ELEM Biotech creates virtual humans and accelerates medical innovation with Oracle Cloud

With its Alya Red technology, the company runs 3D simulations on virtual patients of pacemakers, artificial valves, coronary stents, anti-arrhythmic drugs or drug pumps

Madrid—12 February 2020

ELEM Biotech, biomedical spin-off of the Barcelona Supercomputing Centre established in Barcelona and Bristol, UK, partners with Oracle Cloud Infrastructure High-Performance Computing (HPC) to create virtual humans and accelerate the development and validation of new medical treatments.

ELEM, which generates 3D models of human organs from patient scans, replicates their operation on supercomputers, providing an almost unlimited virtual clinical trials platform based on virtual patients.

Using an infrastructure-as-a-service (IaaS) model implemented in Oracle Cloud Infrastructure, the user, through the biomedical interface of the Alya Red virtual human platform, configures and runs advanced simulations and analyzes them in detail.

Thanks to the simulation engine and the cloud database, it is possible, for example, to simulate obstructive lung diseases or to replicate the functioning of pacemakers, valve replacements, stents, anti-arrhythmic drugs, and treatments for asthma or drug pumps.

"Our virtual humans, which reduce animal and human testing, as well as product cost and time to market, are created in the Oracle Cloud Infrastructure, where medical device manufacturers, pharmaceutical companies and researchers can analyze their products and optimize treatments to better meet patient needs," said Chris Morton, CEO of ELEM Biotech.

Alya has been developed for 15 years at the Barcelona Supercomputing Center - Centro Nacional de Supercomputación (BSC-CNS) using MareNostrum, one of the most powerful supercomputers in Europe. But to bring these developments to market, the company needed a new platform to host commercial clients who wanted to run Alya Red as a software-as-a-service application.

Public High Performance Computing (HPC) resources offer exceptional spaces for the development and validation of new supercomputer tools, but often do not provide the service agility, global scalability, cyber security services or access required for the commercial deployment of a platform like Alya Red. "That's where Oracle solves the problem with its global HPC instances and cloud infrastructure. With Oracle Startup Ecosystem and Oracle Cloud Infrastructure's HPC offering, ELEM Biotech is bringing to market a disruptive and unique technology for the biomedical ecosystem," said the executive.

Alya Red is running on Oracle Cloud Infrastructure HPC instances, using up to 1,000 cores. The results are extremely promising: "We are seeing the same scalability in Oracle Cloud Infrastructure HPC that we see in our dedicated MareNostrum cluster [located at the BSC], and we can retrieve the results without waiting. It is worth mentioning that the code, which was adjusted for MareNostrum, was compiled and executed in Oracle Cloud Infrastructure instances without requiring any additional library or adjustment, really plug&play", explains Mariano Vazquez, CTO of ELEM Biotech.

From ELEM Biotech they believe that "with Oracle Cloud Infrastructure, Alya Red will progressively include more systems and human organs, all of them validated and certified by regulatory agencies for their context of use", assure Chris and Mariano.

Contact Info
Oracle Ibérica
916267454, 610712617
About Oracle

The Oracle Cloud offers a complete suite of integrated applications for Sales, Service, Marketing, Human Resources, Finance, Supply Chain and Manufacturing, plus Highly Automated and Secure Generation 2 Infrastructure featuring the Oracle Autonomous Database. For more information about Oracle (NYSE: ORCL), please visit us at


Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

Talk to a Press Contact

Oracle Ibérica

  • 916267454, 610712617